anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Peanut allergy is known to cause severe anaphylactic reactions. Compared with other food allergies it tends to be more persistent and also its prevalence seems to be rising. Currently there is no proven treatment other than strict avoidance. We are attempting to decrease the risk of anaphylaxis on accidental ingestion by desensitizing subjects to peanut using peanut oral immunotherapy (OIT). We are also studying the effect of peanut OIT on the peanut specific immune response to determine if tolerance to peanut protein will develop. Children ages one to six years of age with peanut allergy will be randomized to peanut OIT or placebo (active subjects). Thirty subjects will also be recruited as controls. These subjects will not receive any peanut or placebo but only have skin prick testing and lab work in addition to a history and physical exam. Active subjects will undergo a modified rush immunotherapy on the first day and then increase the doses at least every two weeks up to a maintenance dose of 4 grams (equivalent to about 13 peanuts). Doses will be taken daily at home except for dose increases which will be done on the research unit. Outcome variables of interest include response to double-blind placebo controlled food challenge, skin prick testing, peanut specific IgE, and adverse events. These results will be compared between the start and end of peanut OIT using appropriate statistical analysis.
This work presents an algorithm for the detection and classification of QRS complexes based on the continuous wavelet transform (CWT) with splines. This approach can evaluate the CWT at any integer scale and the analysis is not restricted to powers of two. The QRS detector comprises four stages: implementation of CWT with splines, detection of QRS complexes, searching for undetected QRS complexes, and correction of the R wave peak location in detected QRS complexes. After, the onsets and ends of the QRS complexes are detected. The algorithm was evaluated with synthetic ECG and with the manually annotated databases: MIT-BIH Arrhythmia, European ST-T, QT and PTB Diagnostic ECG. Evaluation results of the QRS detector were: MIT-BIH arrhythmia database (109,447 beats analyzed), sensitivity Se = 99.72% and positive predictivity P+ = 99.87%; European ST-T database (790522 beats analyzed), Se = 99.92% and P+ = 99.55% and QT database (86498 beats analyzed), Se = 99.97% and P+ = 99.99%. To evaluate the delineation algorithm of the QRS onset (Qi) and QRS end (J) with the QT and PTB Diagnostic ECG databases, the mean and standard deviations of the differences between the automatic and manual annotated location of these points were calculated. The standard deviations were close to the accepted tolerances for deviations determined by the CSE experts. The proposed algorithm is robust to noise, artifacts and baseline drifts, classifies QRS complexes, automatically selects the CWT scale according to the sampling frequency of the ECG record used, and adapts to changes in the heart rate, amplitude and morphology of QRS complexes.
The invention discloses a preparation method and application of a novel phototherapy nano preparation based on polyhedral oligomeric silsesquioxane (POSS). The phototherapy nanometer preparation is prepared by carrying out chemical crosslinking reaction on amino of POSS and carboxyl of photosensitizer to form nanometer particles and then carrying out surface pegylation. The nanometer preparation uses a photosensitizer as a part by using a chemical crosslinking method, realizes ultrahigh drug loading, avoids the early leakage of the drug and inhibits the self-quenching effect of the photosensitizer. Meanwhile, the medicine has good water dispersibility, stability and biological safety. In addition, the phototherapeutic formulation is capable of being largely endocytosed by cancer cells and efficiently killing cancer cells under light conditions. In-vivo animal experiments prove that the phototherapy nano preparation can be enriched to a tumor area through passive targeting, and the imaging and photodynamic therapy of tumors are realized.
The first aim of this revised proposal is to accurately assess the duration and trajectories of smoking abstinence symptoms and associated biobehavioral indices across 66 days of quitting smoking in 3 different treatment groups: 1) bupropion SR (BUP), 2) transdermal nicotine patch (TNP), and 3) placebo patch plus placebo pill. Study sensitivity and accuracy will be maximized by using procedures designed to maximize abstinence and minimize study dropout. The second aim is to characterize brain and psychological mechanisms by which BUP and TNP promote abstinence. While the efficacies of BUP and TNP in promoting smoking abstinence have been repeatedly demonstrated, little is known about the mechanisms mediating this efficacy. The final primary goal of this competitive continuation proposal is to characterize individual differences in psychological and brain mechanisms mediating the beneficial effects of BUP and TNP on smoking abstinence and withdrawal symptoms. A secondary goal is to assess the ability of a battery of innovative brain and biobehavioral measures of attention and affect to predict relapse.

To achieve these goals, the effects of quitting smoking with or without the help of TNP and BUP will be assessed intensively across 66 days of abstinence. Dependent measures will be mood, vigilance, attentional bias to smoking and emotional stimuli, and related physiological measures (resting EEG activation and activation asymmetry indices of affective states and traits, and event-related potential activity elicited by emotional and smoking stimuli). Smokers will be randomly assigned to one of three immediate-quit groups (N = 60 per group): (1) bupropion + placebo patch, (2) placebo pill + nicotine patch, and (3) placebo patch + placebo pill; or to a fourth (control) group (N = 40) that will quit after the final experimental session (after the other subjects have completed their 66-day\* abstinence period). Subjects in the 3 treatment groups and the control group will have the same set of biobehavioral measures assessed during the experimental sessions at the same points in time. It is hypothesized that BUP and TNP will have both common and unique mechanisms by which they reduce withdrawal symptoms and that gender and personality traits will moderate the effects of these treatments. (Note.\* To avoid final-session mood and arousal effects subjects will actually quit for 67 days, but biobehavioral measures will be collected on the 66th day of abstinence.)
<P>PROBLEM TO BE SOLVED: To provide a medical information processing system which can easily, quickly access necessary medical information in a specific situation.  <P>SOLUTION: A storage means 101 stores medical information. A designation means 102 preliminarily designates part of specific information, which is used in a specific situation, among the medical information stored in the storage means 101. An acquisition means 103 makes a terminal device used in the specific situation acquire only the specific information designated by the designation means 102. Thus, the medical information processing system makes the terminal device used in the specific situation acquire only the designated specific information. Consequently, the load on the system is reduced, and the terminal device can quickly acquire the specific information. The system may be provided with a display means which displays the specific information acquired by the acquisition means 103 on the terminal device. The system may be also provided with a patient-reception means which receives the designation of a patient on the display screen of the terminal device. The display means may display a list of specific information on patients designated by the patient-reception means.  <P>COPYRIGHT: (C)2007,JPO&INPIT
All selected patients received conventional ventilation with protective lung strategy for 10 days with Controlled mechanical ventilation mode(CMV), fraction inspired oxygen (FIO2) of 100%, Positive end expiratory pressure(PEEP) of 10 cm H2O or more to achieve target arterial oxygen saturation(SPO2) of 90% or more with sedation by midazolam infusion to achieve Richmond Agitation- Sedation Scale (RASS) -2 to -3 and fentanyl infusion for pain control between 50-100 mg/min. Protective lung strategy was strictly applied in form of head elevation more than 30°, broad spectrum antibiotics according to our antibiotic regimen, daily assessment for both analgesic and sedative dose were given to patients, early naso-gastric feeding started to prevent ventilator associated pneumonia and daily trial was done to reduce PEEP to prevent more lung injury from ventilation also qualitative sputum culture was taken after one week from ventilation. After 10 days from the conventional ventilation those who could not be weaned from the ventilator and still had the former criteria mentioned before (Uncompensated hypercapnia with PH\<7.25, and/or Hypoxic index less than 200) included in our study. Percutaneous dilatation tracheostomy done for all patients in both groups. 60 patients randomly allocated in 2 groups. Randomization sequence was created using Excel 2007 (Microsoft, Redmond, WA, USA) with a 1:1 allocation using random block sizes of 2 and 4 by an independent doctor. In this way, sequence generation and type of randomization can be expressed at the same time. Each group included 30 patients. Patients of group A received inhalation of nitric oxide stared by 50 parts/billion(ppb) as starting dose titrated according to patient's saturation reaching to 90 ppb as a maximum dose. While patients of group B received 4 gram of vitamin c slowly intravenous once daily for 4 days duration. Improvement of general condition of the patients monitored in our study by APACH II score and core body temperature. improvement of the lungs condition monitored in our study clinically by monitoring: oxygen saturation, hypoxic index, compliance and response to recruitment maneuver ( Recruitment maneuver is considered clinical test of lung compliance and start by increase the peak inspiratory pressure to 40 cm/H2O for 40 sec and observe the saturation (SpO2) if improved to more than 95% considered responder in our study).(18) and radiologically by size of parenchymatous lung infiltration on chest X ray. The duration of the study 16 days
Subjects will receive Dabrafenib 150 mg twice daily orally plus Trametinib 2 mg once daily orally on a continuous basis. A treatment cycle is 28 days in duration. Subjects will continue treatment until an unacceptable toxicity, disease progression, or death occurs.
Teratogenic Effects. Pregnancy Category B: Administration of guanfacine to rats at 70 times the maximum recommended human dose and to rabbits at 20 times the maximum recommended human dose resulted in no evidence of harm to the fetus. Higher doses (100 and 200 times the maximum recommended human dose in rabbits and rats respectively) were associated with reduced fetal survival and maternal toxicity. Rat experiments have shown that guanfacine crosses the placenta.

  


There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
NRF is a novel inhibitory transcription factor binding to specific DNA sequences and silencing transcriptional activity of proximal DNA-binding activators, e.g. NF-KB binding sites. NRF is a modulator protein of NF-KB family members controlling genes of significant biomedical importance such as those encoding inflammatory cytokines, MHC proteins, cell adhesion molecules, and viruses. Based on this it represents a molecular target in the development of novel anti-inflammatory therapies for a variety of pathologic disorders such as ischemia, hemorrhagic and septic shock, allograft rejection, bacterial meningitis, acute airway inflammation and the pulmonary complications induced by cardiopulmonary bypass. Furthermore, this might apply for certain cancers and other diseases. NRF as a target for drugs (obtained e.g. by IITS) is protected. Agonists as well as antagonists of NRF are also protected. Further applications such as the use of NRF protein and its fusion proteins or NRF DNA sequence in sense or antisense orientation in gene therapy are also protected.
PURPOSE:A seaweed component-containing cosmetic free from fish-like smell of seaweed characteristics, comprising an extracted solution which is obtained by extracting seaweeds such as laver, etc., with a hydrous organic solvent and concentrating as an active ingredient. CONSTITUTION:Seaweeds (e.g. laver, sea tangle or Higikia fusifome Okamura) are extracted with 50-90% hydrous organic solvent (e.g. ethanol or methanol) at 50-100 deg.C for 20-120min, an extracted solution is concentrated to give a cosmetic and a bathing agent containing the concentrated extracted solution or a dried material thereof as an active ingredient. Water-soluble components such as amino acid, saccharide, mineral, water-soluble vitamin, etc., and fat- soluble components such as fatty acid, steroid, fat-soluble vitamin, etc., can be simultaneously extracted by the extraction. The amount of the extracted solution of the seaweeds is preferably 0.1-10pts.wt. when 0.1-50wt% concentrated solution is used.
This cohort study retrospectively analyzed data from 62 centers in 18 countries, mostly members of the Oncoplastic Breast Consortium (OPBC) network. Patients with clinical T1-4 N0-3 breast cancer at diagnosis treated with neoadjuvant chemotherapy between March 2008 and May 2022 were included if they had isolated tumor cells only. ITCs were defined as clusters of tumor cells ≤0.2 mm or clusters of \<200 cells in a single cross-sectional image, determined by sentinel lymph node biopsy, targeted axillary dissection, or the MARI procedure (marking axillary lymph nodes with radioactive iodine seeds). Excluded: patients with inflammatory breast cancer, stage IV disease at presentation, axillary lymph node dissection as a primary procedure, and neoadjuvant endocrine therapy. Also excluded cases with micrometastases or macrometastases in any sentinel lymph nodes at frozen section or final pathology, and those where ITCs were detected by One Step Nucleic Acid Amplification.
The invention relates to the technical field of medical informatization, in particular to a medical data acquisition and analysis system. A medical data aggregation statistical analysis system, comprising: the system comprises a personal identification data acquisition terminal, a mechanism data acquisition terminal and a data application request terminal. The personal identification data acquisition terminal generates an encrypted x-ID by using personal data, and the encrypted x-ID is interactively connected with the organization data acquisition terminal. The organization data collection end aggregates the x-ID and the health information data contained in the x-ID. The data application request terminal is used for providing an anonymization data operation environment. The invention provides a data analysis system and a data processing method, which carry out anonymous analysis and processing from beginning to end on health data of a same person who visits a medical institution for many times, converge and gather to form a health data set of a person, are beneficial to the reasonable application of medical data and simultaneously play the aim of strictly protecting personal privacy.
The application discloses a formula and a preparation method of gynecological antibacterial gel. The gel is mainly composed of water, carbomer, jojoba oil, oat glucan and various plant extracts. The preparation method comprises the steps of weighing raw materials, pre-dispersing, heating for dissolving, uniformly mixing, filling into a container, sterilizing, controlling quality, finally packaging and the like. The gel has antibacterial, antiinflammatory, and moisturizing effects, and is suitable for gynecological care. In a preferred formulation, the water is purified water and the carbomer model is carbomer 2020. The quality control of the product comprises detection of indexes such as appearance, pH value, stability and the like. The finished product is stored at a constant temperature, a dry place and a cool place, so that direct sunlight and a humid environment are avoided, and the quality and the validity period of the product are ensured. Compared with chemically synthesized antibiotics, the application has fewer side effects and better biodegradability, and is more friendly to human health and environment.
The proposed study will use a randomized clinical trial design to examine the effectiveness of centralized disease management (CDM) versus counseling alone (C) for smoking cessation. Hospitalized smokers in 30 rural critical access hospitals will be randomly assigned to either CDM (n=303) or C (n=303). Participants in both arms of the study will receive in-hospital smoking cessation counseling via telephone followed by 4 outpatient telephone-based counseling calls. The content and timing of these counseling calls are designed to emulate models of smoking cessation counseling that have been previously shown to be effective for hospitalized smokers. For recipients assigned to CDM, the counseling will be streamlined to allow time on the calls for specific disease management interventions, including screening for contraindications to pharmacotherapy and linking medication choices to the smoker's insurance coverage. After completing calls with CDM participants, the Tobacco Treatment Specialists will coordinate therapy with the patient's health care providers by providing them with brief consultation reports, prepared order sheets for inpatient treatment, and outpatient prescription requests. Six months postdischarge, participants in both groups will be contacted again, and persistent or relapsed smokers will be offered another cycle of the C or CDM intervention.

Assessments will be conducted at baseline and at months 3, 6, and 12. The primary outcome of interest will be biochemically verified 7-day point prevalence abstinence at 12 months. Secondary endpoints include number of quit attempts and number of cigarettes smoked (among continuing smokers), pharmacotherapy utilization, duration of pharmacotherapy utilization, and the extent of discussions with the healthcare provider. We will also examine the marginal cost-effectiveness of the intervention.
Females under age 18 years old are the fastest-growing segment of the juvenile justice population and are at risk for negative co-occurring outcomes including drug abuse, HIV/STI risk, criminal behavior, and educational failure. As they enter young adulthood, this constellation of behaviors puts them at heightened risk for early parenthood and subsequent involvement in the child welfare system (for their parenting behaviors) and the adult corrections system (for criminal behaviors). Such system involvement is costly, and its prevention would be of great significance to public health; however, very little is known about factors leading to females' success/failure in young adulthood and factors that might prevent involvement in these two public systems. This study aims to further our understanding of the pathways to and the prevention of HIV/STI risk, drug use, and child welfare and adult corrections involvement by following-up 166 women who participated in two randomized intervention trials aimed at reducing delinquency during adolescence. In the original studies, juvenile justice girls who had been referred for out-of-home placement due to chronic delinquency were randomly assigned to services as usual or to Treatment Foster Care Oregon (TFCO, formerly known as MTFC). Efficacy of the intervention with this sample has been shown at 12- and 24-month follow-ups on criminal referral rates, days spent in locked settings, deviant peer associations, educational engagement, and pregnancy prevention. The investigators propose to examine the developmental pathways for these juvenile justice girls into young adulthood (ages 21-28 years) using innovative data collection and data analytic techniques, with foci on the long-term effects of TFCO, the mediators of young adult adjustment and child welfare/corrections involvement, and the cost effectiveness and cost avoidance of TFCO on these outcomes. The overarching aim is to identify potential targets for subsequent intervention. One in-person assessment is proposed with each female and her current romantic partner (if she has one); in addition, telephone interviews will be conducted every 6 months for the duration of the study, and system data from child welfare and adult corrections will be collected.
They were examined with manual auscultation of the thorax and where necessary, with chest X-ray or CT scan. They wore the WELMO sensors vest for a period of 15-20 minutes during which the vest recorded the breathing provided by the mechanical ventilator.
Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at the preliminary recommended Phase 2 dose (RP2D).
Provided herein is a novel and useful device and method for locally delivering and controllably releasing oxybutynin in the cervical region of a female. A device of the invention comprises a ring comprising trifluoropropylmethyl/dimethyl siloxane elastomer. A pharmaceutical composition comprising oxybutynin and an excipient is placed within a bore located in the ring, wherein the bore runs from the surface of the ring into the ring. The ring has a sufficient size such that it can be inserted into the vaginal canal of a female. A cap comprising is placed over the bore at the surface of the ring in order to contain the pharmaceutical composition within the bore. When the ring is inserted into the vaginal canal, the trifluoropropylmethyl/dimethyl siloxane elastomer controllably releases and locally delivers a therapeutically effective amount of oxybutynin to the detrusor muscle to treat the female's urinary incontinence.
MOTIVATION: Genome-wide association studies (GWAS) have enabled large-scale analysis of the role of genetic variants in human disease. Despite impressive methodological advances, subsequent clinical interpretation and application remains challenging when GWAS suffer from a lack of statistical power. In recent years, however, the use of information diffusion algorithms with molecular networks has led to fruitful insights on disease genes.
RESULTS: We present an overview of the design choices and pitfalls that prove crucial in the application of network propagation methods to GWAS summary statistics. We highlight general trends from the literature, and present benchmark experiments to expand on these insights selecting as case study three diseases and five molecular networks. We verify that the use of gene-level scores based on GWAS P-values offers advantages over the selection of a set of 'seed' disease genes not weighted by the associated P-values if the GWAS summary statistics are of sufficient quality. Beyond that, the size and the density of the networks prove to be important factors for consideration. Finally, we explore several ensemble methods and show that combining multiple networks may improve the network propagation approach.
45 patients classified as ASA P1 or P2 aged between 18 and 65 candidates for elective knee operation via arthroscopy were included in the study. All patients received femoral nerve block guided by ultrasound with bupivacaine, 22 ml. The first patient at a concentration of 0.25%. The other patients with higher or lower concentrations if the first patient has pain\> 3 or \<3 on visual analogic scale respectively after awakening of surgical anesthesia. For surgical anesthesia each patient will undergo general anesthesia. At the end of the surgical procedure and anesthetic awakening patients will be evaluated for analgesia by verbal numeric scale. The modified Dixon method was used to find the EC50 and EC95 of bupivacaine for analgesia of femoral nerve block guided by ultrasound. Concentration still correlated with motor block and side effects.